Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Needs Alternative To Labels To Change Behavior, IoM Safety Cmte. Says

Executive Summary

FDA needs to develop a more proactive tool to change prescribing behavior rather than relying on labeling, panelists said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System
Advertisement

Related Content

FDA Needs Quantitative Risk/Benefit Analysis To Quell Industry Approval Fears
FDA Needs Quantitative Risk/Benefit Analysis To Quell Industry Approval Fears
FDA Should Reassess Patient Information Sheet Proposal, NCPIE Says
FDA Should Reassess Patient Information Sheet Proposal, NCPIE Says
Advertisement
UsernamePublicRestriction

Register

PS046782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel